CoChat
Sign Up
Cited by 268Immune Cell Function and Interactioninterferon and immune responsesImmunotherapy and Immune Responses

NK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists

Open access
Nicolai, Christopher J., Wolf, Natalie, Chang, I-Chang, Kirn, Georgia, Marcus, Assaf, Ndubaku, Chudi O., McWhirter, Sarah M., Raulet, David H.·2020·Science Immunology
DOI 10.1126/sciimmunol.aaz2738PMC PMC7228660
Open this paper in CoChat — free account

Abstract

STING agonists trigger NK cell–mediated clearance of MHC-deficient tumors resistant to CD8 + T cells and NK-sensitive, MHC-expressing tumors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciimmunol.aaz2738

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Direct activation of the host STING pathway through intratumoral injections of synthetic cyclic dinucleotides is an attractive therapeutic strategy in multiple preclinical cancer models.

    “Direct activation of the host STING pathway through intratumoral injections of synthetic cyclic dinucleotides has shown to be an attractive therapeutic strategy in multiple preclinical cancer models22,25,42.”

    From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [42]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 54

  1. [1]Sharma P, Allison JP, The future of immune checkpoint therapy. Science 348, 56– 61 (2015). 25838373
  2. [2]Ribas A, Wolchok JD, Cancer immunotherapy using checkpoint blockade. Science 359, 1350– 1355 (2018). 29567705 PMC7391259
  3. [4]Leach DR, Krummel MF, Allison JP, Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734– 1736 (1996). 8596936
  4. [5]McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C, Consortium TR, Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell 171, 1259– 1271 e1211 (2017). 29107330 PMC5720478
  5. [6]Roemer MG, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, Connelly CF, Pak CJ, Carey CD, Daadi SE, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Shipp MA, Rodig SJ, Classical Hodgkin Lymphoma with Reduced beta2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunol Res 4, 910– 916 (2016). 27737878 PMC5210180
  6. [7]Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T, The urgent need to recover MHC class I in cancers for effective immunotherapy. Current opinion in immunology 39, 44– 51 (2016). 26796069 PMC5138279
  7. [10]Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, Wang L, Shifrin N, Raulet DH, Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 122, 91– 128 (2014). 24507156 PMC4228931
  8. [11]Cerwenka A, Lanier LL, Natural killer cells, viruses and cancer. Nature Rev Immunol 1, 41– 49. (2001). 11905813
  9. [12]Raulet DH, Guerra N, Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 9, 568– 580 (2009). 19629084 PMC3017432
  10. [13]Raulet DH, Gasser S, Gowen BG, Deng W, Jung H, Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31, 413– 441 (2013). 23298206 PMC4244079
  11. [14]Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L, Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19, 197– 223 (2001). 11244035
  12. [15]Karre K, Ljunggren HG, Piontek G, Kiessling R, Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675– 678 (1986). 3951539
  13. [16]Karlhofer FM, Ribaudo RK, Yokoyama WM, MHC class I alloantigen specificity of Ly-49+ IL-2 activated natural killer cells. Nature 358, 66– 70 (1992). 1614533
  14. [17]Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L, Receptors for HLA class-I molecules in human natural killer cells. Ann. Rev. Immunol. 14, 619– 648 (1996). 8717527
  15. [18]Raulet DH, Vance RE, Self-tolerance of natural killer cells. Nat Rev Immunol 6, 520– 531 (2006). 16799471
  16. [19]Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF, A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med 24, 1178– 1191 (2018). 29942093 PMC6475503
  17. [20]Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis ESC, NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell 172, 1022– 1037 e1014 (2018). 29429633 PMC5847168
  18. [21]Chen Q, Sun L, Chen ZJ, Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol 17, 1142– 1149 (2016). 27648547
  19. [23]Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M, Hayakawa Y, Hammond MC, Vance RE, The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep 3, 1355– 1361 (2013). 23707065 PMC3706192
  20. [24]Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Rohl I, Hopfner KP, Ludwig J, Hornung V, cGAS produces a 2’−5’-linked cyclic dinucleotide second messenger that activates STING. Nature 498, 380– 384 (2013). 23722158 PMC4143541
  21. [25]Lam AR, Le Bert N, Ho SS, Shen YJ, Tang ML, Xiong GM, Croxford JL, Koo CX, Ishii KJ, Akira S, Raulet DH, Gasser S, RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma. Cancer Res 74, 2193– 2203 (2014). 24590060 PMC4229084
  22. [26]Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF, STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830– 842 (2014). 25517615 PMC4384884
  23. [27]Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH, Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. Immunity 49, 754– 763 e754 (2018). 30332631 PMC6488306
  24. [28]Zhu Q, Man SM, Gurung P, Liu Z, Vogel P, Lamkanfi M, Kanneganti TD, Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J Immunol 193, 4779– 4782 (2014). 25320273 PMC4308418
  25. [29]Luteijn RD, Zaver SA, Gowen BG, Wyman SK, Garelis NE, Onia L, McWhirter SM, Katibah GE, Corn JE, Woodward JJ, Raulet DH, SLC19A1 transports immunoreactive cyclic dinucleotides. Nature 573, 434– 438 (2019). 31511694 PMC6785039
  26. [31]Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR, STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity 41, 843– 852 (2014). 25517616 PMC5155593
  27. [33]Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr., Gajewski TF, Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep 11, 1018– 1030 (2015). 25959818 PMC4440852
  28. [34]Francica BJ, Ghasemzadeh A, Desbien AL, Theodros D, Sivick KE, Reiner GL, Hix Glickman L, Marciscano AE, Sharabi AB, Leong ML, McWhirter SM, Dubensky TW Jr., Pardoll DM, Drake CG, TNFalpha and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors. Cancer Immunol Res 6, 422– 433 (2018). 29472271 PMC6215542
  29. [35]Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, Gaide O, Michielin O, Hwu P, Petrova TV, Martinon F, Modlin RL, Speiser DE, Gilliet M, STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A 112, 15408– 15413 (2015). 26607445 PMC4687570
  30. [36]Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W, Sivick KE, Zeng Q, Soares KC, Zheng L, Portnoy DA, Woodward JJ, Pardoll DM, Dubensky TW Jr., Kim Y, STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Science translational medicine 7, 283ra252 (2015). PMC4504692 25877890
  31. [37]Curran E, Chen X, Corrales L, Kline DE, Dubensky TW Jr., Duttagupta P, Kortylewski M, Kline J, STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Rep 15, 2357– 2366 (2016). 27264175 PMC5116809
  32. [38]Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, Hertzog P, Smyth MJ, Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 178, 7540– 7549 (2007). 17548588
  33. [39]Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C, Weber JS, Weirather JL, Wolchok JD, Postow MA, Pavlick AC, Chesney J, Hodi FS, MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science translational medicine 10, (2018). 30021886
  34. [41]Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A, Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med 375, 819– 829 (2016). 27433843 PMC5007206
  35. [42]Narni-Mancinelli E, Chaix J, Fenis A, Kerdiles YM, Yessaad N, Reynders A, Gregoire C, Luche H, Ugolini S, Tomasello E, Walzer T, Vivier E, Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc Natl Acad Sci U S A 108, 18324– 18329 (2011). 22021440 PMC3215049
  36. [43]Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH, The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17, 19– 29. (2002). 12150888
  37. [45]Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, Tough DF, Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99, 3263– 3271 (2002). 11964292
  38. [46]Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD, Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208, 1989– 2003 (2011). 21930769 PMC3182061
  39. [47]Mortier E, Woo T, Advincula R, Gozalo S, Ma A, IL-15R{alpha} chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 205, 1213– 1225 (2008). 18458113 PMC2373851
  40. [48]Becknell B, Caligiuri MA, Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 86, 209– 239 (2005). 15705423
  41. [50]Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW, Zhang L, Iannello A, Mathur N, Jardine KE, Kirn GA, Bell JC, McBurney MW, Raulet DH, Ardolino M, Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest 128, 4654– 4668 (2018). 30198904 PMC6159991
  42. [51]Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, Kim S, Kim G, Chon HJ, Kim C, STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest 130, 4350– 4364 (2019). 31343989 PMC6763266
  43. [53]Dunn GP, Koebel CM, Schreiber RD, Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6, 836– 848 (2006). 17063185
  44. [54]Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, Gotthardt D, Warsch W, Eckelhart E, Kantner HP, Kalinke U, Lienenklaus S, Weiss S, Strobl B, Muller M, Sexl V, Stoiber D, Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology 1, 1027– 1037 (2012). 23170251 PMC3494617
  45. [55]Degli-Esposti MA, Smyth MJ, Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 5, 112– 124 (2005). 15688039
  46. [56]Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A, Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J Immunol 173, 3594– 3598 (2004). 15356102
  47. [57]Mortier E, Advincula R, Kim L, Chmura S, Barrera J, Reizis B, Malynn BA, Ma A, Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. Immunity 31, 811– 822 (2009). 19913445
  48. [58]Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A, Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26, 503– 517 (2007). 17398124 PMC2084390
  49. [59]Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, Bilocq AM, Kirilovsky A, Tosolini M, Waldner M, Berger A, Fridman WH, Rafii A, Valge-Archer V, Pages F, Speicher MR, Galon J, Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Science translational medicine 6, 228ra237 (2014). 24648340
  50. [60]Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, Sun R, Tian Z, Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19, 723– 732 (2018). 29915296
  51. [61]Meazza R, Azzarone B, Orengo AM, Ferrini S, Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol 2011, 861920 (2011). PMC3118299 21716670
  52. [62]Ardolino M, Azimi CS, Iannello A, Trevino TN, Horan L, Zhang L, Deng W, Ring AM, Fischer S, Garcia KC, Raulet DH, Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 124, 4781– 4794 (2014). 25329698 PMC4347250
  53. [63]Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, Xu J, Rovis TL, Xiong N, Raulet DH, Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 348, 136– 139 (2015). 25745066 PMC4856222
  54. [64]Thompson TW, Kim AB, Li PJ, Wang J, Jackson BT, Huang KTH, Zhang L, Raulet DH, Endothelial cells express NKG2D ligands and desensitize anti-tumor NK responses. Elife 6, e30881 (2017). PMC5792093 29231815

Cited by

Sorted by citations

Authors
Nicolai, C. J., Wolf, N., Chang, I.-C., Kirn, G., Marcus, A., Ndubaku, C. O., McWhirter, S. M., & Raulet, D. H.
Affiliations
  • University of California, Berkeley (US)
  • Aduro BioTech (United States) (US)
Corresponding author
Raulet, David H.
ORCID
Venue
Science Immunology
Publisher
American Association for the Advancement of Science (AAAS)
Published
2020-03-13
Volume
5
Issue
45
ISSN
2470-9468 (ISSN-L)
DOI
10.1126/sciimmunol.aaz2738
PMC
PMC7228660
OpenAlex
W3012207340
Cited by
268
References
10
Citations by year
2026: 34 · 2025: 52 · 2024: 61 · 2023: 33 · 2022: 36 · 2021: 39 · 2020: 13
FWCI
10.60
Type
journal article
Language
en
Open access
Locations
  • Science Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • NIH Office of the Director (R01-AI113041, F31CA228381)
  • Immunotherapy and Vaccine Research Initiative (IVRI) supported by Aduro Biotech (045535)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
natural killer cells, STING agonist, tumor clearance, type I interferon, IL-15 receptor alpha, dendritic cells, NK cell activation, cancer immunotherapy, NK cell engagers, immune checkpoint inhibitors
MeSH terms
STING Protein, Animals, Interferon Type I, Killer Cells, Natural, Membrane Proteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms, Tumor Cells, Cultured, Mice, Knockout, CD8-Positive T-Lymphocytes, Mice, Congenic, Mice, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review